Role of Sirolimus in Treatment of Microcystic , Mixed Lymphatic and Vascular Malformations

Inclusion Criteria: * from age 6 months to 12 years , not before 6 months to complete their vaccination program \& maturation of hepatic enzymes . * Patients diagnosed with microcystic \& mixed Lymphatic malformations . * After failure of other lines of treatment as regard propranolol , steroid for infantile haemangiomas \& Vascular malformations and lymphovascular malformations . * After failure of surgical excision \& injection of bleomycin of Lympho-vascular malformations Exclusion Criteria: * Macrocystic Lymphatic malformations \& high flow vascular malformations like arterio-venous malformations . * An active infection that requires systemic treatment during the attack . * Side effects of the drug as ( history of an allergic reaction to sirolimus or patients who develop severe allergic reaction to drug during treatment , hyperlipidemia , leucopenia , etc… ) * Chronic liver or kidney disease or on chronic drug treatment as (steroids, interferon or chemotherapeutic agents) . * An immunodeficiency condition such as a human immunodeficiency viral infection or primary immunodeficiency disease. * Patients who received drug less than 6 months duration .